ZBH’s 3Q16 worldwide YoY product pricing was -1.8%, which is close to what it has been for many consecutive quarters.
Yet despite today’s sell-off, ZBH (the stock) has had a fabulous run during the past few years.
So, why is a market environment with flat to slightly negative pricing ok for a medical-device company, but (supposedly) not ok for a drug/biotech company?
Market Data 
Markets 
AI
